Pharmacokinetic Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition

Inclusion Criteria: * Male aged between 18 and 35 years (inclusive) at screening. * No clinically significant findings on the physical examination at screening. * Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) and body weight at least 50 kg at screening. * Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg and heart rate (HR) 45-90 bpm (inclusive). * 12-lead electrocardiogram (ECG) without clinically relevant abnormalities at screening. * Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening. * Ability to communicate well with the investigator and to understand and comply with the requirements of the study. Exclusion Criteria: * Known hypersensitivity to any excipients of the drug formulations. * Treatment with another investigational drug within 30 days prior to screening. * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. * Positive results from urine drug screen at screening. * Excessive caffeine consumption, defined as \>800 mg per day at screening\*. * African or Hispanic ethnicity. * History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity. * Smoking within the last 3 months prior to screening. * Previous treatment with any prescribed or OTC medications (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of study. * Loss of 250 ml or more of blood within 3 months prior to screening. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. * Legal incapacity or limited legal capacity at screening.